Competition In The Pharmaceutical Industry Research Paper

PAGES
3
WORDS
986
Cite

Johnson & Johnson: Three of the Five Forces

Introduction

Johnson and Johnson is a multinational pharmaceutical company that operates in a highly competitive industry. The three forces of competition in the industry, potential of new entrants, and power of suppliers are significant factors that affect the company's business operations and success. This paper provides an analysis of these three forces and their impact on Johnson and Johnson.

Relevance of the Three Forces to the Pharmaceutical Industry

The three forces of competition in the industrypotential of new entrants, and power of suppliersare critical factors that affect the pharmaceutical industry's operations and success (Porter; Sultana). There are many reasons for this. First off, competition in the pharmaceutical industry is intense, and companies must continually innovate and develop new drugs to stay ahead of the curve (Olasiuk). This was seen recently in 2020 as companies tried to be the first to market with a COVID vaccine. To compete in this industry, moreover, it requires significant investment in research and development, clinical trials, and regulatory approvals, all of which can be expensive and time-consuming. The competition is also driven by the need to lower costs and improve patient outcomes, which puts pressure on companies to develop more effective and affordable treatments. Overall, the competition in the industry drives innovation and ensures that patients have access to high-quality, affordable treatments.

Secondly, the potential for new entrants is significant in the pharmaceutical industry, as advances in technology and biotechnology have made it easier for smaller companies to develop new drugs and therapies (Leeuw et al.). This poses a threat to established companies that may struggle to keep up with new innovations and technology. The potential for new entrants also creates competition, which can drive innovation and reduce costs. However, new entrants may also face significant barriers to entry, such as regulatory requirements, capital requirements, and intellectual property protections.

Finally, the power of suppliers is relevant in the pharmaceutical industry because companies require a steady supply of raw materials, such as...…regulatory bodies and invest in compliance measures to maintain its position in the market.

Power of Suppliers

Pharmaceutical companies require a steady supply of raw materials, including active pharmaceutical ingredients (APIs) and excipients, to manufacture drugs. The power of suppliers in the industry is relatively high, as there are few suppliers of high-quality APIs and excipients. The suppliers can exert pressure on pharmaceutical companies by increasing prices or reducing supply, which can affect the company's ability to manufacture drugs (Gassmann et al.).

To manage the power of suppliers, Johnson and Johnson must develop strong relationships with suppliers and maintain a diverse range of suppliers to avoid supply chain disruptions. The company must also invest in alternative sources of raw materials and maintain a strong bargaining position to negotiate favorable terms with suppliers.

Conclusion

In conclusion, Johnson and Johnson operate in a highly competitive industry that demands continuous innovation and differentiation to stay ahead of the curve. The potential threat of new entrants and the power of suppliers are significant challenges that…

Sources Used in Documents:

Works Cited

Gassmann, Oliver, et al. "The Industry Challenge: Who Would Want to Be in ThisBusiness?." Leading Pharmaceutical Innovation: How to Win the Life Science Race (2018): 17-39.

Leeuw, Bas J. de, Peter de Wolf, and Frans AJ den van Bosch. "The changing role of technologysuppliers in the pharmaceutical industry: the case of drug delivery companies." International Journal of Technology Management 25.3-4 (2003): 350-362.

Olasiuk, Hanna. "Competitive forces on the Ukrainian pharmaceutical market: Evaluationaspects." Journal of Applied Management and Investments 6.3 (2017): 186-196.

Porter, Michael E. "The five competitive forces that shape strategy." Harvard businessreview 86.1 (2008): 78.

Prayogi, Reynaldy, and Harimukti Wandebori. "Proposed Strategy for Pharmaceutical Industry(Case Study: PT Bio Farma Persero)." European Journal of Business and Management Research 5.5 (2020).

Sultana, Jesmin. "Future prospects and barriers of pharmaceutical industries inBangladesh." Bangladesh Pharmaceutical Journal 19.1 (2016): 53-57.


Cite this Document:

"Competition In The Pharmaceutical Industry" (2023, March 30) Retrieved April 29, 2024, from
https://www.paperdue.com/essay/competition-pharmaceutical-industry-research-paper-2178654

"Competition In The Pharmaceutical Industry" 30 March 2023. Web.29 April. 2024. <
https://www.paperdue.com/essay/competition-pharmaceutical-industry-research-paper-2178654>

"Competition In The Pharmaceutical Industry", 30 March 2023, Accessed.29 April. 2024,
https://www.paperdue.com/essay/competition-pharmaceutical-industry-research-paper-2178654

Related Documents

This relationship has an effect on the payment rates that CMS sets. Higher cost pharmaceutical therapies are systematically reimbursed below acquisition cost (i.e., the payment system is biased against full reimbursement for higher cost therapies). Reimbursement compared to acquisition cost for the top IO pharmaceuticals by total expenditures indicates that 9 of the 10 are significantly under reimbursed." Clinical Trials Report: Congress established Medicare beneficiaries numbering 40 million with a prescription

38 per share on the company's common stock for the first quarter of 2005. The dividend is payable January 3, 2005 to stockholders of records at the close of business on December 3, 2004. Growth in the ZETIA and VYTORIN franchises are expected to continue. T There are currently several candidates in Phase III that Merck plans to file in 2005 as well as Type 2 diabetes treatment and three vaccines.

There are two constant irritations in U.S. pharma companies' relationships internationally: Some developing nations, such as India, Brazil and South Africa, are chipping away at the patent situation, trying to shorten the time until the drugs can be brought out in generic form. The U.S. has supported high prices as the cost for innovation. Since other countries are not playing along, this means that their citizens are benefiting from the innovation paid

For example, before its paten ran out, "the price of Schering-Plough's top-selling allergy pill, Claritin, was raised thirteen times over fives years, for a cumulative increase of more than 50%, over four times the rate of general inflation." In 2002, the average price of the fifty drugs most used by senior citizens was approximately $1,500 for a year's supply, and although this refers to what the companies call the

McKesson Corporation (Mckesson) is an American pharmaceutical distributor with operations mainly in the U.S. The firm has been in operation since 1833, and boasts extensive market share, robust financial strength, and strong market power. The firm has built strong relationships with its key stakeholders, which adds to its strengths. Nonetheless, limited diversification and market focus as well as the threats of competition, unfavourable regulatory changes, and counterfeits present significant concerns

Pharmaceutical Ethics Issues Generally, business ethics is a concept that has not been upheld or exemplified to any high standard by the modern pharmaceutical industry. It is an industry frequently plagued by unethical marketing decisions and practices, the pursuit of business strategies and policies that violate public trust in spirit if not necessarily in the written word, and that has embraced research practices that are sometimes highly questionable. In the modern